Pfizer and Merck release 2-year update on PD-L1 immunotherapy Bavencio

MCC is a rare invasive skin cancer, clinical prognosis is very poor, metastatic MCC mortality rate is higher than melanoma, 1 year survival rate is not more than 50%, 5 yearsurvival rate is not more than 20%recently, Pfizer and Merck presented updates for two years on the two-year follow-up of THE key phase II clinical study jaVELIN Merkel 200 for the treatment of metastatic Merkel cell carcinoma (mMCC) at theof the American Society of Clinical Oncology's annualmeeting (ASCO2018)BavencioBavencio, a PD-L1 tumor immunotherapy, was approved in March 2017 as the world's first immunotherapy treatment for mMCCBavencio's launch marks a major milestone in the clinical treatment of mMCCrelated studies
this study is an international, multi-center, open label, single-group PHASE II study, conducted in 88 patients who have been certified to mMCC by histological lynosology, mainly elderly patients (median age 72.5 years, range: 33 -88 years old) and has previously undergone at least one course of chemotherapy (59.1% for 1, 29.5% for 2, 11.4% for 3 and above) to control far-end metastasis but progress during or after chemotherapyinstudies, patients received Bavencio (10 mg/kg, intravenous infusion every 2 weeks) until the disease progressed or was unacceptable lysotoxicData for the median follow-up of 29.2 months (range: 24.8-38.1 months)show that the total mitigation rate (ORR) was 33% (95% CI: 23.3-43.8), of which the full mitigation rate was 11.4%, which remained unchanged from the previously published median follow-up months 12th and 18th monthsOf the 29 patients with remission, 19 remained remission and 12 continued for more than 2 yearsThe persistent mitigation rate also resulted in a stable rate of progression: 29 per cent, 29 per cent and 26 per cent, respectively, in the 12th, 18th and 24th monthsThe median total lifetime (OS) was 12.6 months (95% CI: 7.5-17.1) and the 2-year survival rate was 36% (50% and 39%, respectively, at 12th and 18th months)data for at least 2 years of follow-up showed no new security signals for Bavencio, and the security was consistent with previously reported